AbbVie: Deepen and expand cooperation with Chinese companies to incubate more first-class drugs in China

Author:Khvaja
Release time:Sep 18, 2024 13:30 PM

In recent years, while foreign-funded pharmaceutical companies have continued to increase their investment in China, they have also been promoting the optimization and upgrading of the domestic pharmaceutical industry chain. The exchanges and cooperation between multinational pharmaceutical companies and domestic companies have gradually become an important channel for domestic companies to share and absorb experience and resources.

AbbVie, a world-renowned pharmaceutical company, recently launched the "China Cooperation Day" event in Shanghai again. Unlike previous events, this "China Cooperation Day" was the first offline event.

Dr. Nicholas Donohue spoke at AbbVie's "China Collaboration Day" event

"China Cooperation Day provides a platform for our Chinese partners to gain an in-depth understanding of our corporate strategy, and also provides us with an excellent platform to discuss potential areas of cooperation with many industry leaders." Dr. Nicholas Donohue, AbbVie's global executive vice president, chief business and strategy officer, introduced that AbbVie has held the "China Cooperation Day" event every year since 2021. Through the "China Cooperation Day", AbbVie is committed to deepening and expanding its cooperative relationship with the Chinese biopharmaceutical industry chain, including the participation and cooperation with industry scholars, biotechnology companies and venture capitalists.

"AbbVie highly values ​​and deeply recognizes the value of collaboration with Chinese partners. With our strong global network, we share international expertise with Chinese partners and help them connect with global resources," emphasized Dr. Nicholas Donohue.

It is reported that the offline event of "China Cooperation Day" organized by AbbVie was held at the St. Regis Hotel in Jing'an, Shanghai. AbbVie shared the company's strategy, target treatment areas and cooperation methods, etc., hoping to work with more potential partners in China's industrial chain, capital chain, innovation chain, etc. to accelerate the global development of China's innovative drugs and medical industries, and continuously launch innovative therapies through win-win cooperation.

As the world's second largest pharmaceutical market, China's huge market size and growth potential have attracted the attention of global pharmaceutical giants. With the rapid development of the industry, the research and development capabilities of my country's biopharmaceutical companies have continued to increase, and the cooperation between domestic innovative pharmaceutical companies and multinational pharmaceutical companies has accelerated.

"The rapidly changing Chinese market is a major opportunity for AbbVie and any other global biopharmaceutical company. There are more and more exciting business opportunities for Chinese biotech companies." Dr. Nicholas Donohoe said that from the perspective of the entire industry, licensing agreements from China have increased significantly. "At AbbVie, more than 17% of the agreements we signed this year were signed with Chinese companies. I believe that we will see more and more cooperation opportunities for first-class drugs to emerge from China and trade these assets with global biopharmaceutical companies such as AbbVie."

According to reports, on June 13 this year, AbbVie and Chinese biopharmaceutical company Mingji Biopharma announced the signing of a licensing agreement to jointly develop FG-M701. FG-M701 is a next-generation TL1A antibody for the treatment of inflammatory bowel disease that is in the preclinical development stage. Compared with the first-generation TL1A antibody, FG-M701 has undergone unique engineering transformation and has the potential to become the best functional properties in its class. This cooperation is also seen by the industry as AbbVie's determination to find more cooperation projects in its deep research and treatment fields, which will also help promote the scientific research and commercial transformation of Chinese innovative drugs around the world.

Fu Pengcheng delivered a speech at AbbVie's "China Cooperation Day" event

"The Chinese pharmaceutical market is of vital importance to AbbVie," said Fu Pengcheng, senior vice president of AbbVie's intercontinental region. Driven by an aging society and residents' growing concern for healthcare, the Chinese pharmaceutical market has entered a new stage of development. AbbVie is a leading global biopharmaceutical company committed to supporting Chinese patients and bringing its first-class innovative drugs to China as soon as possible. AbbVie plans to launch more than 40 new products and indications in the Chinese market by 2030.

According to statistics, since 2013, the number of AbbVie's products in the Chinese market has expanded from 5 to more than 20, covering multiple therapeutic areas such as immunology, oncology, ophthalmology, neuroscience and aesthetics.

As China's innovation capabilities continue to grow, its contribution to global pharmaceutical research and development has gradually increased, and the review of innovative drugs and medical devices has been significantly accelerated. These positive changes have also strengthened the confidence of multinational pharmaceutical companies to deepen their presence in the Chinese market, attracting them to continue to deepen their layout in China.

Fu Pengcheng introduced that in the past 11 years, the number of AbbVie employees in China has grown from about 400 to more than 2,600, including nearly 300 researchers and scientists. "China is currently actively involved in 85% of AbbVie's global multi-center Phase III clinical trials, and there are more than 90 ongoing and planned clinical trials."

"China is committed to creating an environment that encourages innovation, including a sound regulatory framework and intellectual property protection. If it continues this strategy, China will attract numerous multinational pharmaceutical companies to explore opportunities to provide innovation for Chinese patients," said Fu Pengcheng.


AbbVie: Deepen and expand cooperation with Chinese companies to incubate more first-class drugs in China
comment
35th Anniversary of Industrial Bank: Deeply rooted and lush, blooming with fragrance, flowing in Central China, striving to sail with clouds, digitalization | Technology | Industrial Bank
35th Anniversary of Industrial Bank: Deeply rooted and lush, blooming with fragrance, flowing in Central China, striving to sail with clouds, digitalization | Technology | Industrial Bank

In 1979, with the thunderous sound of "turning banks into banks", China's financial reform began. On August 26, 1988, as one of the first joint-stock commercial banks, Industrial Bank emerged on the banks of the Minjiang River in the southeast tide. The 35th anniversary is a scale of time, a ruler of development, and even more so, a step forward. Since its establishment 35 years ago, Industrial Bank has leveraged its unique advantages rooted in Fujian, integrating patriotism into unremitting efforts, keeping pace with the times, the motherland, and the people, adhering to the principle of "exploring paths for financial reform and making more contributions to economic construction", rooting itself in the land of Fujian and extending its branches and leaves to the whole country and the world. It has achieved multi-level cross regional cooperation among regional banks, national banks, listed banks, and banking groups, occupying an important position in domestic and foreign financial markets, and composing the story of "walking well in China"

Shanghai Rural Commercial Bank takes innovative practices as the "vanguard" of serving people's livelihoods. Shanghai Rural Commercial Bank | Finance | Vanguard
Shanghai Rural Commercial Bank takes innovative practices as the "vanguard" of serving people's livelihoods. Shanghai Rural Commercial Bank | Finance | Vanguard

The ancient saying goes, "When you fall, think of your tree, and drink from its source." Modern enterprises are the cells of society, and society is the mother body that nurtures the growth of enterprises. While developing themselves, enterprises should also be good "corporate citizens", think of their roots and repay society. This is an indispensable social responsibility of enterprises and an important part of building a harmonious society. Shanghai Rural Commercial Bank has always taken continuously meeting the growing demand for high-quality financial services from the people as its starting point and foothold, actively grasping the new trends and demands that the people yearn for a better life, and always playing the role of leading and main force in Shanghai's local urban and rural financial services. During this process, stories of actively assuming social responsibility and practicing finance for the people were vividly written. Empowering Urban Governance with Green Finance Green finance is the key to achieving low-carbon transformation in society

Buick Encore Plus with a starting price of 126900 yuan | Buick | Buick Encore Plus
Buick Encore Plus with a starting price of 126900 yuan | Buick | Buick Encore Plus

Recently, SAIC General Motors announced the official launch of the Buick Encore Plus, a Dole Life SUV, with two models available: the Fun Edition and the Smart Edition, priced at 126900 yuan and 136900 yuan respectively. Starting today, users can place a purchase order by paying a deposit of 1000 yuan through the WeChat mini program Buick Buick, iBuick App, and Buick official website. The Buick Encore Plus measures 4458mm in length, 1813mm in width, and 1644mm in height, with a wheelbase of 2640mm. The front and rear rows of the new car have ample headroom, shoulder space, and legroom, especially the legroom and knee space in the rear row reach the leading level of 1002mm and 68mm in the same class, allowing even tall adults to sit comfortably. The rare rear flat floor in the same class not only allows for boarding and alighting

Searching for authentic flavors, exploring the charm of intangible cultural heritage, Leshi Summer Limited New Series Documentary - CCTV premiere of Leshi | Potato Chips | Series
Searching for authentic flavors, exploring the charm of intangible cultural heritage, Leshi Summer Limited New Series Documentary - CCTV premiere of Leshi | Potato Chips | Series

Recently, the Le Shi Summer Limited Series of potato chips has been launched. The sour and spicy taste of Lincang, the hot braised fresh aroma of Wuhan, and the rich sauce aroma of Xi'an have been condensed into three unique new braised potato chips, bringing a refreshing taste experience. At the same time, Le Shi also delves into the traditional cultural charm of the three regions, creating a series of micro documentaries titled "Searching for Authentic Flavors" that are popular on CCTV-6, exploring the regional cultural customs behind different braised flavors, telling stories of the unique and authentic flavors of each potato chip, paying tribute to intangible cultural heritage culture with deliciousness, and bringing consumers a double surprise experience of taste and spirit. Dai culture is the pride of every Yunnan person, and their love for dance has become a part of life. Just like them, they also cannot do without sour, refreshing, and spicy flavors. Joy has penetrated into the mysterious land of the Dai people in Lincang, Yunnan,

Ranked second in the city and first in the suburbs!, Qingpu: The growth rate of large-scale soft information industry has reached 34%. Technology | Soft Information Industry | City wide
Ranked second in the city and first in the suburbs!, Qingpu: The growth rate of large-scale soft information industry has reached 34%. Technology | Soft Information Industry | City wide

Since the beginning of this year, the soft information industry in Qingpu District has grown rapidly, with a continuous increase in year-on-year growth rate. The latest statistical data shows that from January to April, the operating revenue of enterprises in the information transmission, software, and information technology services industry in Qingpu District was 13.3 billion yuan, with a year-on-year growth rate continuously increasing from 17.5% in January to February to 34% in January to April, ranking second in the city; It is estimated that the year-on-year growth rate from January to May will exceed 40%. The soft information industry is the cornerstone of the digital industry, a strategic emerging industry that gathers high-end talents and optimizes industrial structure. To develop the soft information industry, Qingpu has resources, advantages, and prospects. Since the 14th Five Year Plan, Qingpu has aimed to build a leading digital industry development goal, comprehensively promoted the implementation of the "Yangtze River Delta Digital Trunk" strategy, accelerated the introduction of various industrial policies, and continuously expanded the investment scale of digital economy projects and key enterprises